Background and Objectives: A bone–patellar tendon–bone (BTB) autograft in anterior cruciate ligament reconstruction (ACLR) is still considered the gold standard among many orthopedic surgeons, despite anterior knee pain and kneeling pain being associated with bone defects at the harvest site. Bioregenerative products could be used to treat these defects, perhaps improving both the postoperative discomfort and the overall reconstruction. Materials and methods: During a year-long period, 40 patients were enrolled in a pilot study and divided into a study group, in which bone defects were filled with Vivostat® PRF (platelet-rich fibrin), and a standard group, in which bone defects were not filled. The main outcome was a decrease in the height and width of the bone defects, as determined by magnetic resonance imaging on the control exams during the one-year follow-up. The secondary outcomes included an evaluation of kneeling pain, measured with a visual analog scale (VAS), and an evaluation of the subjective knee scores. Results: The application of Vivostat® PRF resulted in a more statistically significant reduction in the width of the defect compared with that of the standard group, especially at 8 and 12 months post operation (p < 0.05). Eight months following the surgery, the study group’s anterior knee pain intensity during kneeling was statistically considerably lower than that of the standard group (p < 0.05), and the statistical difference was even more obvious (p < 0.01) at the last follow-up. Each control examination saw a significant decrease in pain intensity in both the groups, with the values at each exam being lower than those from the prior exam (p < 0.01). A comparison of subjective functional test results 12 months post operation with the preoperative ones did not prove a statistically significant difference between the groups. Conclusions: The use of Vivostat® PRF reduces kneeling pain and accelerates the narrowing of bone defects after ACLR with a BTB graft, but without confirmation of its influence on the subjective knee score.
29 April 2025 in Annals of Agricultural and Environmental Medicine
Introduction and objective: This study aims to compare operative and non-operative treatments for Distal Radius Fracture (DRF) in elderly patients, and to monitor the prevalence of Post-traumatic Arthritis (PA) over a period of 2 years. Despite numerous guidelines for the treatment of DRF,...
Background and Objectives: Despite the high rate of donor site morbidity, a bone–patellar tendon–bone (BPTB) graft remains the gold standard when choosing a graft for anterior cruciate ligament (ACL) reconstruction. Damage to the infrapatellar branch of the saphenous nerve (IPBSN) during graft harvesting results in sensory deficits. Despite its high occurrence in the postoperative period, many patients go untreated, leading to a lower quality of life and potential professional impairment. The aim of this study was to assess the effectiveness of PRF therapy in alleviating sensory deficits and enhancing sensory nerve function in patients who have undergone BTB ACL reconstruction. Materials and Methods: This study was registered at ClinicalTrials.gov (Name of registry: ClinicalTrials.gov; Trial registration number: NCT07257666; Date of registration: 2 December 2025; Study start date: 7 January 2022). Over a one-year period, the pilot study enrolled 53 patients, treated them with BPTB ACL reconstruction, and divided them into two groups. The testing group’s donor site and subcutaneous tissue were treated with Vivostat® PRF, whereas the standard group’s donor site and subcutaneous tissue remained untreated. The primary outcome measured was a reduction in the subjective numbness, which was tested during follow-up checks. Secondary outcomes included the evaluation of subjective knee scores for functional recovery, reported by the patients on control exams. Results: The use of Vivostat® PRF resulted in a statistically significant reduction in sensory deficit among the groups at eight months (p < 0.05) and twelve months (p < 0.01) following surgery, favoring the testing group. The most substantial decrease in symptomatic patients was observed between four and eight months post-surgery, with no statistically significant difference found between the eight- and twelve-month follow-ups (p > 0.05). Evaluations of subjective knee function and activity scores showed no statistically significant differences between the groups. Conclusions: Using Vivostat® PRF helps reduce sensory impairment in the area and minimizes donor site morbidity after BPTB ACL reconstruction.
Introduction: Hand injuries often result in soft tissue defects. The treatment of these defects belongs to the most difficult challenges in reconstructive surgery. There are numerous options for covering soft tissue defects, including flaps and skin grafts. Material and methods: This retrospective observational study included seventeen patients with 24 skin defects of the hand, who were treated by primary split-thickness skin graft (STSG) in a single center. The average follow-up period was 6 months. The age of the patients ranged from 36 to 80 years. The majority of patients (n=16) were males, and one patient was female. Skin defects varied in size from 7x8mm to 39x40mm. Primary goals were STSG survival, recipient site infection, and donor site morbidity. Secondary goals were cosmetic appearance and time needed for complete wound healing. Results: All 24 wounds healed successfully in a mean of 28,11±9,94 days. There were no graft infections. Partial graft loss occurred in one case. There was no major donor site morbidity reported. Six patients described the cosmetic result as good (score 3), 10 patients dde-scribed it as acceptable (score 2), and one patient described it as poor (score 1). Conclusion: Split thickness skin graft is an excellent option for immediate treatment of hand and finger skin defects. This method is simple , has less consequences than secondary grafts, requires minimum equipment and can sometimes be done in the emergency room, without hospitalization. Therefore, there is no need to be afraid of primary skin grafting.